NO884024D0 - Tumor-immunoterapi under anvendelse av antiidiotypeantistoffer. - Google Patents
Tumor-immunoterapi under anvendelse av antiidiotypeantistoffer.Info
- Publication number
- NO884024D0 NO884024D0 NO1988884024A NO884024A NO884024D0 NO 884024 D0 NO884024 D0 NO 884024D0 NO 1988884024 A NO1988884024 A NO 1988884024A NO 884024 A NO884024 A NO 884024A NO 884024 D0 NO884024 D0 NO 884024D0
- Authority
- NO
- Norway
- Prior art keywords
- tumor
- antibody
- idiotypic antibodies
- administration
- idiotype
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 7
- 238000009169 immunotherapy Methods 0.000 title abstract 3
- 230000003302 anti-idiotype Effects 0.000 title 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 230000003053 immunization Effects 0.000 abstract 2
- 238000002649 immunization Methods 0.000 abstract 2
- 230000006698 induction Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 230000001629 suppression Effects 0.000 abstract 1
- 239000002512 suppressor factor Substances 0.000 abstract 1
- 230000005951 type IV hypersensitivity Effects 0.000 abstract 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57476—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofetal proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9609587A | 1987-09-10 | 1987-09-10 | |
| US07/116,802 US4918164A (en) | 1987-09-10 | 1987-11-04 | Tumor immunotherapy using anti-idiotypic antibodies |
| US07/225,446 US5614610A (en) | 1984-12-21 | 1988-07-28 | Tumor immunotherapy using anti-idiotypic antibodies |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| NO884024D0 true NO884024D0 (no) | 1988-09-09 |
| NO884024L NO884024L (no) | 1989-03-13 |
| NO178464B NO178464B (no) | 1995-12-27 |
| NO178464C NO178464C (no) | 1996-04-03 |
Family
ID=27378089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO884024A NO178464C (no) | 1987-09-10 | 1988-09-09 | Monoklonalt antiidiotypeantistoff og fremgangsmåte for in vitro overvåkning av antiidiotypeantistoffer i en pröve fra en pasient som er under behandling |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5614610A (no) |
| EP (2) | EP0306995B1 (no) |
| JP (1) | JPH02494A (no) |
| AT (1) | ATE151079T1 (no) |
| AU (1) | AU630592B2 (no) |
| DE (1) | DE3855850T2 (no) |
| DK (1) | DK500888A (no) |
| ES (1) | ES2102978T3 (no) |
| FI (1) | FI884114A (no) |
| GR (1) | GR3023725T3 (no) |
| HU (1) | HU206394B (no) |
| IL (1) | IL87692A (no) |
| NO (1) | NO178464C (no) |
| NZ (1) | NZ226129A (no) |
| OA (1) | OA08952A (no) |
| PT (1) | PT88459B (no) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60255209A (ja) * | 1984-05-30 | 1985-12-16 | Mitsubishi Heavy Ind Ltd | 圧延機におけるエツジヤ開度制御方法 |
| AU607533B2 (en) * | 1987-08-07 | 1991-03-07 | Xoma Corporation | Methods and compositions for mimicking antigenic determinants |
| US6805862B1 (en) | 1989-05-25 | 2004-10-19 | Sloan-Kattering Institute For Cancer Research | Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof |
| US6432402B1 (en) | 1989-05-25 | 2002-08-13 | Sloan-Kettering Institute For Cancer Research | Anti-idiotypic antibody which induces an immune response against a glycosphingolipid and use thereof |
| DE69032855T2 (de) * | 1989-05-25 | 1999-08-12 | Sloan-Kettering Institute for Cancer Research, New York, N.Y. | Antiidiotypischer antikörper, der eine immunantwort gegen ein glykosphingolipid induziert und seine verwendung |
| DE69033295T2 (de) * | 1989-11-03 | 2000-05-25 | David M. Euhus | Nachweismethode für Harnkarzinom-assoziierte Antigene |
| JPH04148298A (ja) * | 1990-10-08 | 1992-05-21 | Matsushita Electric Ind Co Ltd | 違法駐車検出警告装置 |
| DE4208795A1 (de) * | 1992-03-19 | 1993-09-23 | Behringwerke Ag | Monoklonaler anti-gangliosid-antikoerper, seine herstellung und verwendung als tumortherapeutikum |
| SE470285B (sv) * | 1992-05-22 | 1994-01-10 | Volvo Penta Ab | Drivaggregat för fartyg |
| US5861158A (en) * | 1993-11-17 | 1999-01-19 | The United States Of America As Represented By The Deptartment Of Health And Human Services | Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor |
| US7354587B1 (en) * | 1994-07-06 | 2008-04-08 | Immunomedics, Inc. | Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines |
| US5798100A (en) * | 1994-07-06 | 1998-08-25 | Immunomedics, Inc. | Multi-stage cascade boosting vaccine |
| WO2001002013A1 (en) * | 1999-07-02 | 2001-01-11 | Lifetime Pharmaceuticals, Inc. | Predicting immunotherapy effectiveness through delayed type hypersensitivity |
| EP1221961A4 (en) * | 1999-10-13 | 2004-03-31 | Roswell Park Memorial Inst | INDUCTION OF A STRONG IMMUNE RESPONSE TO A TUMOR-RELATED SELF-ANTIGEN |
| EP1638587A4 (en) | 2003-02-14 | 2007-04-18 | Univ Missouri | RECIPROCAL PROCEDURES AND COMPOSITIONS CONCERNING PROTEASOMAL INTERFERENCE |
| AT500650B1 (de) | 2003-04-17 | 2009-11-15 | Altropus Gmbh | Immunogener rekombinanter antikörper |
| DE10352977A1 (de) * | 2003-11-13 | 2005-06-09 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Muriner anti Idiotyp-Antikörpers oder anti Idiotyp-Antikörper aus der Ratte des humanen monoklonalen SC-1 Antikörpers |
| US20110020273A1 (en) * | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| US8652484B2 (en) | 2004-02-13 | 2014-02-18 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
| US8491914B2 (en) * | 2004-02-13 | 2013-07-23 | Ibc Pharmaceuticals, Inc. | Dock-and-lock (DNL) complexes for delivery of interference RNA |
| US20110064754A1 (en) * | 2005-03-03 | 2011-03-17 | Center For Molecular Medicine And Immunology | Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines |
| US9481878B2 (en) | 2004-02-13 | 2016-11-01 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
| US8562988B2 (en) * | 2005-10-19 | 2013-10-22 | Ibc Pharmaceuticals, Inc. | Strategies for improved cancer vaccines |
| US8551480B2 (en) | 2004-02-13 | 2013-10-08 | Immunomedics, Inc. | Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity |
| US8435539B2 (en) * | 2004-02-13 | 2013-05-07 | Immunomedics, Inc. | Delivery system for cytotoxic drugs by bispecific antibody pretargeting |
| JP4929864B2 (ja) | 2006-06-15 | 2012-05-09 | 株式会社デンソー | 配管継手装置 |
| CN102186499B (zh) * | 2008-08-20 | 2015-05-20 | Ibc医药公司 | 用于癌症治疗的对接和锁定(dnl)疫苗 |
| JP5985481B2 (ja) * | 2010-09-01 | 2016-09-06 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | 抗イディオタイプ抗体の迅速な産生 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0720884B2 (ja) * | 1983-11-07 | 1995-03-08 | ザ・ウイスタ−・インスティテュ−ト | 抗イデイオタイプ抗体によって誘発される、腫瘍およびウイルスに対する免疫応答 |
| JPS60155133A (ja) * | 1983-11-09 | 1985-08-15 | シンビオテイツクス コ−ポレイシヨン | アンチ−イデイオタイプのモノクロナル抗体を採用したアンチ−イデイオタイプワクチン |
| US4699880A (en) * | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| US4906562A (en) * | 1984-12-21 | 1990-03-06 | Oncogen | Monocolonal antibodies and antigen for human non-small cell lung carcinomas |
| US4918164A (en) * | 1987-09-10 | 1990-04-17 | Oncogen | Tumor immunotherapy using anti-idiotypic antibodies |
-
1988
- 1988-07-28 US US07/225,446 patent/US5614610A/en not_active Expired - Fee Related
- 1988-09-07 FI FI884114A patent/FI884114A/fi not_active Application Discontinuation
- 1988-09-07 IL IL8769288A patent/IL87692A/en not_active IP Right Cessation
- 1988-09-08 PT PT88459A patent/PT88459B/pt not_active IP Right Cessation
- 1988-09-09 HU HU884647A patent/HU206394B/hu not_active IP Right Cessation
- 1988-09-09 EP EP88114834A patent/EP0306995B1/en not_active Expired - Lifetime
- 1988-09-09 NO NO884024A patent/NO178464C/no unknown
- 1988-09-09 DK DK500888A patent/DK500888A/da not_active Application Discontinuation
- 1988-09-09 AU AU22077/88A patent/AU630592B2/en not_active Ceased
- 1988-09-09 DE DE3855850T patent/DE3855850T2/de not_active Expired - Fee Related
- 1988-09-09 JP JP63224877A patent/JPH02494A/ja active Pending
- 1988-09-09 AT AT88114834T patent/ATE151079T1/de active
- 1988-09-09 ES ES88114834T patent/ES2102978T3/es not_active Expired - Lifetime
- 1988-09-09 OA OA59429A patent/OA08952A/xx unknown
- 1988-09-09 EP EP96111623A patent/EP0759442A1/en not_active Withdrawn
- 1988-09-12 NZ NZ226129A patent/NZ226129A/en unknown
-
1997
- 1997-06-11 GR GR970401369T patent/GR3023725T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL87692A (en) | 1994-04-12 |
| AU630592B2 (en) | 1992-11-05 |
| EP0759442A1 (en) | 1997-02-26 |
| US5614610A (en) | 1997-03-25 |
| HU206394B (en) | 1992-10-28 |
| ATE151079T1 (de) | 1997-04-15 |
| GR3023725T3 (en) | 1997-09-30 |
| AU2207788A (en) | 1989-03-16 |
| OA08952A (fr) | 1990-11-30 |
| DE3855850T2 (de) | 1997-11-20 |
| FI884114A (fi) | 1989-03-11 |
| EP0306995B1 (en) | 1997-04-02 |
| EP0306995A3 (en) | 1990-03-07 |
| PT88459B (pt) | 1993-01-29 |
| NZ226129A (en) | 1991-12-23 |
| EP0306995A2 (en) | 1989-03-15 |
| FI884114A0 (fi) | 1988-09-07 |
| DE3855850D1 (de) | 1997-05-07 |
| JPH02494A (ja) | 1990-01-05 |
| NO884024L (no) | 1989-03-13 |
| NO178464B (no) | 1995-12-27 |
| ES2102978T3 (es) | 1997-08-16 |
| DK500888A (da) | 1989-03-11 |
| NO178464C (no) | 1996-04-03 |
| DK500888D0 (da) | 1988-09-09 |
| HUT47973A (en) | 1989-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO884024D0 (no) | Tumor-immunoterapi under anvendelse av antiidiotypeantistoffer. | |
| DK0626390T3 (da) | Humaniserede antistoffer | |
| MD1374G2 (ro) | Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică | |
| Hála et al. | A monoclonal antibody reacting with a membrane determinant expressed on activated chicken T lymphocytes | |
| ATE137533T1 (de) | Monoklonale antikörper gegen melanom | |
| EP0420848A4 (en) | Carcinoma-associated antigens, and antibodies which recognize these antigens | |
| DK102589A (da) | Antigen, der genkendes af mca 16-88 | |
| Theofilopoulos | Immune complexes in humoral immune responses: suppressive and enhancing effects | |
| EP0537168A4 (en) | Ctaa 28a32, the antigen recognized by mca 28a32 | |
| Ma et al. | Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response | |
| DE69024758D1 (de) | Neuartige antiidiotypische monoklonale Antikörper | |
| Hekman et al. | Increased expression of a normal lymphocyte membrane antigen on chronic lymphatic leukemia cells | |
| Abromson-Leeman et al. | Analysis of insulin-specific T cell clones. I. Strategy for production of clonotypic antibody. | |
| Saito et al. | Induction of chronic idiotype suppression by ligands binding to the variable (not the constant) region of the idiotypic target | |
| Velge-Roussel et al. | Functional analysis of a T cell line specific for antiidiotypic antibodies to a Schistosoma mansoni protective epitope. I. Role in the anti-S. mansoni antibody response. | |
| RU93032579A (ru) | Способ лечения аутоиммунных заболеваний и лейкозов с аутоиммунными проявлениями | |
| DE3786695D1 (de) | Tumorassoziiertes antigen. |